Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Neurology

Stroke

Histone deacetylase 6 (HDAC6)

Studies in mice suggest HDAC6 inhibitors could be useful for treating ischemic stroke. In a mouse model of ischemic stroke, a selective HDAC6 inhibitor increased expression of regulatory T cell markers and decreased infarct size compared with vehicle. Next steps could include testing HDAC6 inhibitors in other preclinical stroke models.
Celgene Corp. and Acetylon Pharmaceuticals Inc. have the HDAC6 inhibitor ACY-1215 in Phase I/II testing to treat multiple myeloma (MM).
Karus Therapeutics Ltd. has HDAC6 inhibitors in preclinical development to treat cancer and inflammation.

SciBX 6(48); doi:10.1038/scibx.2013.1397
Published online Dec. 19, 2013

Patent and licensing status undisclosed

Liesz, A. et al. J. Neurosci.;
published online Oct. 30, 2013;
doi:10.1523/JNEUROSCI.4901-12.2013
Contact: Roland Veltkamp, Heidelberg University, Heidelberg, Germany
e-mail:
roland.veltkamp@med.uni-heidelberg.de